PCSK9 and atherosclerosis: Treatment with the PCSK9 inhibitor SBC-115076 up-regulated ABCA1 and ABCG1 expression in plaque macrophages, restored cholesterol efflux capacity, reduced lipid deposition, and simultaneously lowered plasma Hcy levels while improving the lipid profile, thereby attenuating atherosclerosis severity [52].